Hemorrhage is a leading cause of death from severe trauma. Hemoglobin blood substitutes(HBOC) have a number of advantages in treating hemorrhage including improved availabilty withdecreased storage demands. Prolong Pharmaceuticals has developed a PEGylated bovinehemoglobin (PEG-Hb) that is designed to enhance the delivery of oxygen to tissues. In the Phasel component of this Fast-Track SBIR contract we will begin to optimize the production of thismaterial as a starting point for large scale production of PEG-Hb in the Phase II SBIR contract. In this phase II component of the Fast-Track SBIR contract, we will develop and implement thescale-up production of PEG-Hb developed in the phase I SBIR. This wil involve three paralleltasks including the large scale purification of bovine hemoglobin and synthesis of PEG-Hb in itsappropriate formulation
